MedTrace Logo

Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor

NCT00437463 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-11-18

No results posted yet for this study

Summary

To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.

Conditions

Interventions

DRUG

Ramipril

2.5mg and increase to 5mg if patient do not develop symptomatic hypotension

Sponsors & Collaborators

Principal Investigators

  • Daniel Yuen · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00437463 on ClinicalTrials.gov